Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals (Nasdaq: PHAT), a biopharmaceutical company specializing in gastrointestinal treatments, has announced its management team's participation in four major healthcare investor conferences. The schedule includes Guggenheim's Inaugural Healthcare Innovation Conference in Boston (Nov 12), Stifel 2024 Healthcare Conference in New York (Nov 18), Jefferies London Healthcare Conference (Nov 20), and 7th Annual Evercore HealthCONx Conference in Coral Gables (Dec 3). Live webcasts will be available for most events, with recordings accessible for 90 days on the company's website.
Phathom Pharmaceuticals (Nasdaq: PHAT), un'azienda biotecnologica specializzata in trattamenti gastrointestinali, ha annunciato la partecipazione del suo team di gestione a quattro importanti conferenze per investitori nel settore sanitario. Il programma include il Guggenheim's Inaugural Healthcare Innovation Conference a Boston (12 novembre), il Stifel 2024 Healthcare Conference a New York (18 novembre), il Jefferies London Healthcare Conference (20 novembre) e il 7th Annual Evercore HealthCONx Conference a Coral Gables (3 dicembre). Saranno disponibili webcast dal vivo per la maggior parte degli eventi, con registrazioni accessibili per 90 giorni sul sito web dell'azienda.
Phathom Pharmaceuticals (Nasdaq: PHAT), una empresa biofarmacéutica especializada en tratamientos gastrointestinales, ha anunciado la participación de su equipo directivo en cuatro importantes conferencias de inversores en el sector de la salud. El calendario incluye la Inaugural Healthcare Innovation Conference de Guggenheim en Boston (12 de noviembre), la Stifel 2024 Healthcare Conference en Nueva York (18 de noviembre), la Jefferies London Healthcare Conference (20 de noviembre) y la 7th Annual Evercore HealthCONx Conference en Coral Gables (3 de diciembre). Habrá transmisiones en vivo disponibles para la mayoría de los eventos, con grabaciones accesibles durante 90 días en el sitio web de la empresa.
Phathom Pharmaceuticals (Nasdaq: PHAT), 위장관 치료를 전문으로 하는 생명공학 회사는 관리 팀이 네 개의 주요 의료 투자자 회의에 참여할 것이라고 발표했습니다. 일정에는 Guggenheim의 첫 번째 의료 혁신 회의가 보스턴(11월 12일), Stifel 2024 의료 회의가 뉴욕(11월 18일), Jefferies 런던 의료 회의(11월 20일) 및 제7회 Evercore HealthCONx 회의가 코랄 게이블스(12월 3일)에서 열릴 예정입니다. 대부분의 이벤트는 실시간 웹캐스트로 제공되며, 회사 웹사이트에서 90일 동안 녹화된 내용을 볼 수 있습니다.
Phathom Pharmaceuticals (Nasdaq: PHAT), une entreprise biopharmaceutique spécialisée dans les traitements gastro-intestinaux, a annoncé la participation de son équipe de direction à quatre grandes conférences pour investisseurs dans le secteur de la santé. Le programme comprend la Guggenheim's Inaugural Healthcare Innovation Conference à Boston (12 novembre), la Stifel 2024 Healthcare Conference à New York (18 novembre), la Jefferies London Healthcare Conference (20 novembre) et la 7th Annual Evercore HealthCONx Conference à Coral Gables (3 décembre). Des webcasts en direct seront disponibles pour la plupart des événements, avec des enregistrements accessibles pendant 90 jours sur le site web de l'entreprise.
Phathom Pharmaceuticals (Nasdaq: PHAT), ein biopharmazeutisches Unternehmen, das sich auf gastrointestinale Behandlungen spezialisiert hat, hat die Teilnahme seines Managementteams an vier wichtigen Investorenkonferenzen im Gesundheitswesen bekanntgegeben. Der Zeitplan umfasst die Guggenheim's Inaugural Healthcare Innovation Conference in Boston (12. November), die Stifel 2024 Healthcare Conference in New York (18. November), die Jefferies London Healthcare Conference (20. November) und die 7th Annual Evercore HealthCONx Conference in Coral Gables (3. Dezember). Für die meisten Veranstaltungen werden Live-Webcasts verfügbar sein, und Aufzeichnungen sind 90 Tage lang auf der Website des Unternehmens zugänglich.
- None.
- None.
FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November and December:
Guggenheim’s Inaugural Healthcare Innovation Conference in Boston, MA
Date: Tuesday, November 12, 2024
Live Webcast: 9:30 am ET
Management to participate in one-on-one meetings throughout the conference
Stifel 2024 Healthcare Conference in New York, NY
Date: Monday, November 18, 2024
Live Webcast: 1:15 pm ET
Management to participate in one-on-one meetings throughout the conference
Jefferies London Healthcare Conference in London, UK
Date: Wednesday, November 20, 2024
Management to participate in one-on-one meetings throughout the conference
7th Annual Evercore HealthCONx Conference in Coral Gables, FL
Date: Tuesday, December 3, 2024
Live Webcast: 2:10 pm ET
Management to participate in one-on-one meetings throughout the conference
To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 90 days following the conclusion of each meeting.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2024 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
What investor conferences will Phathom Pharmaceuticals (PHAT) attend in November 2024?
When is Phathom Pharmaceuticals (PHAT) presenting at the Evercore HealthCONx Conference 2024?
How long will Phathom Pharmaceuticals (PHAT) conference webcasts be available for viewing?
What time is Phathom Pharmaceuticals (PHAT) presenting at the Guggenheim Healthcare Conference 2024?
